J. HERMAN, M.D.
To the editor: The report by Rosove and colleagues (1) on the ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura underscores the difficulty in determining a therapeutic rationale for a condition of unknown cause, uncertain pathogenesis, and disputed definition (2, 3). The situation is further complicated by the widely differing degrees of severity manifested by this syndrome, which may follow a fulminant and rapidly fatal course, may be subacute and relatively mild (4), or even chronic and relapsing (5). Finally, reporting of treatment has not been standardized and it is often difficult, when perusing a case
HERMAN J. Thrombotic Thrombocytopenic Purpura. Ann Intern Med. ;96:791–792. doi: 10.7326/0003-4819-96-6-791_2
Download citation file:
Published: Ann Intern Med. 1982;96(6_part_1):791-792.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use